MMP-9 enhances the bioavailability of VEGF in the tumour microenvironment by hydrolysing the molecular binding domain of VEGF, thereby activating dormant tumour cells and triggering tumour metastasis (3, 64, 67). The gene discussed is VEGFA; the disease is neoplasm.